A bad year to be an American medtech
Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.
Role reversal for large-cap medtechs
Shareholders are rewarding the kinds of companies they punished a year ago.
Covid-19 divides the biggest medtechs
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
Big cap medtechs see out the decade in style
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
Big cap medtech comes roaring back
Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
2017 saw the stars Align for big-cap medtech
Toothy grins all round at Align, but it is unclear how much longer it can keep up its scorching rate of sales growth.